These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28653209)

  • 41. Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis.
    Sharim J; Tashjian R; Golzy N; Pouratian N
    J Clin Neurosci; 2016 Aug; 30():166-168. PubMed ID: 26970935
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
    Singer B; Ross AP; Tobias K
    Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis.
    Samaraweera AP; Cohen SN; Akay EM; Evangelou N
    Mult Scler; 2016 Jan; 22(1):122-4. PubMed ID: 26219664
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis.
    Tagawa A; Ogawa T; Tetsuka S; Otsuka M; Hashimoto R; Kato H; Ando K; Tanabe H
    Mult Scler Relat Disord; 2016 Sep; 9():155-7. PubMed ID: 27645365
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BASAL CELL CARCINOMA AND SQUAMOUS CELL CARCINOMA IN A PATIENT TREATED WITH FINGOLIMOD FOR MULTIPLE SCLEROSIS - A CASE REPORT AND LITERATURE REVIEW.
    Zięba N; Gębka-Kępińska B; Sowa P
    Wiad Lek; 2022; 75(3):735-741. PubMed ID: 35522887
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fingolimod therapy and macular hemorrhage.
    Bhatti MT; Freedman SM; Mahmoud TH
    J Neuroophthalmol; 2013 Dec; 33(4):370-2. PubMed ID: 23845997
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.
    Yeh EA; Weinstock-Guttman B
    Adv Ther; 2011 Apr; 28(4):270-8. PubMed ID: 21394595
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis.
    Thomas K; Proschmann U; Ziemssen T
    Expert Opin Pharmacother; 2017 Oct; 18(15):1649-1660. PubMed ID: 28844164
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fingolimod: therapeutic mechanisms and ocular adverse effects.
    Mandal P; Gupta A; Fusi-Rubiano W; Keane PA; Yang Y
    Eye (Lond); 2017 Feb; 31(2):232-240. PubMed ID: 27886183
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study.
    Tichá V; Kodým R; Počíková Z; Kadlecová P
    Clin Drug Investig; 2017 Feb; 37(2):175-186. PubMed ID: 27785735
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis.
    Comi G; Hartung HP; Bakshi R; Williams IM; Wiendl H
    Drugs; 2017 Oct; 77(16):1755-1768. PubMed ID: 28905255
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bilateral fingolimod-associated macular oedema development after cataract surgery.
    Gillam M; Richardson T
    BMJ Case Rep; 2021 Jun; 14(6):. PubMed ID: 34088686
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analyses.
    Chinea Martinez AR; Correale J; Coyle PK; Meng X; Tenenbaum N
    Adv Ther; 2014 Oct; 31(10):1072-81. PubMed ID: 25245812
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fingolimod for the treatment of relapsing multiple sclerosis.
    Jeffery DR; Markowitz CE; Reder AT; Weinstock-Guttman B; Tobias K
    Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
    Warrender-Sparkes M; Spelman T; Izquierdo G; Trojano M; Lugaresi A; Grand'Maison F; Havrdova E; Horakova D; Boz C; Oreja-Guevara C; Alroughani R; Iuliano G; Duquette P; Girard M; Terzi M; Hupperts R; Grammond P; Petersen T; Fernandez-Bolaños R; Fiol M; Pucci E; Lechner-Scott J; Verheul F; Cristiano E; Van Pesch V; Petkovska-Boskova T; Moore F; Kister I; Bergamaschi R; Saladino ML; Slee M; Barnett M; Amato MP; Shaw C; Shuey N; Young C; Gray O; Kappos L; Butzkueven H; Kalincik T; Jokubaitis V;
    Mult Scler; 2016 Apr; 22(4):520-32. PubMed ID: 26199347
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acute Anterior Uveitis in a Patient Taking Fingolimod (FTY720) for Multiple Sclerosis.
    Mack HG; Tien MC; White OB
    Case Rep Ophthalmol; 2016; 7(3):284-288. PubMed ID: 28101047
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and Safety of Fingolimod in an Unselected Patient Population.
    Rasenack M; Rychen J; Andelova M; Naegelin Y; Stippich C; Kappos L; Lindberg RL; Sprenger T; Derfuss T
    PLoS One; 2016; 11(1):e0146190. PubMed ID: 26734938
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Delayed high-grade atrioventricular block requiring pacemaker implantation in a multiple sclerosis patient treated with fingolimod.
    Feige J; Schernthaner C; Wipfler P; Sellner J
    Mult Scler Relat Disord; 2020 Feb; 38():101515. PubMed ID: 31751857
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East.
    Achiron A; Aref H; Inshasi J; Harb M; Alroughani R; Bijarnia M; Cooke K; Yuksel O
    BMC Neurol; 2017 Aug; 17(1):150. PubMed ID: 28784108
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A case of dextrocardia following maternal exposure to generic Fingolimod during the first trimester of pregnancy.
    Navardi S; Sahraian MA
    Mult Scler Relat Disord; 2018 Apr; 21():69-70. PubMed ID: 29474980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.